The New England Journal of Medicine (NEJM) recently published an Editorial related to understanding who benefits the most when taking the oral COVID-19 treatment Paxlovid.
Paxlovid (Nirmatrelvir, plus ritonavir) is the first oral small-molecule antiviral agent administered targeting the SARS-CoV-2 virus main protease inhibitor with potent pan–human-coronavirus activity in vitro.
The U.S. FDA and various countries have authorized Paxlovid.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
